Question on Helus Pharma (HELP) and SLS buyout valuation nuances.
Looking at Cybin/Helus’ portfolio had me curious: how DOES one value (in buyout proceedings) other R&D assets such as HELP’s deuterated phenethylamine derivative?
Also would love to see the math again (if anyone has the time) on SLS’ future WT1 targeting applications.